4Salvati EA, Pellegrini VD Jr, Sharrock NE, et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am, 2008,82 ( 2 ) : 252 -270.
2Bristow RE, PoweU MA, AI-Hammadi N.Disparities in ova- dan cancer care quality and survival according to race and socioeconomic status[J].d Natl Cancer lnst, 2013, 105 (11):823.
3Hess LM, Brady WE, Havrilesky LJ.Comparison of meth- ods to estimate health state utilities for ovarian cancer us- ing quality of life data: a Gynecologic Oncology Group study[J].Gynecol Oncol, 2013,128 (2) : 175.
4Crothers BA, Jones BA, Cahilt LA.Quality improvement op- portunities in gynecologic cytologic-histologic correla- tions: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Confer- ence working group 4[J].Arch Pathol Lab Med, 2013, 137 (2):199.
5Thompson SR, Delaney GP, Gabriel GS.Estimation of the optimal brachytherapy utilization rate in the treatment of gynecological cancers and comparison with patterns of care[J].Int J Radiat Oncol Biol Phys , 2013,85 (2) : 400.
8Koracevic G P. Treatment for Deep Vein Thrombosis and Pulmonary Thrornboembolism is A/nost the Sarfle - It Does Not Seem Quite Logical[J]. J Emerg Med, 2013, 45(2) : 49.
9Todeschini P, La Manna G, Dalmastri V, et al.Incidence of late deep venous thrombosis among renal transplant patients[J]. Transplant Proe, 2013, 45 (7) : 2666-2668.
10Lopes L C, Eikelboom J, Spencer F A, et a|.Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis[J].BMJ Open, 2014, 4 ( 7 ): e005 674.
